{'fraction_non_alphanumeric': 0.01818181818181818, 'fraction_numerical': 0.012121212121212121, 'mean_word_length': 5.2, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mitomycin c in the treatment of metastatic transitional cell carcinoma of urinary bladder

Mitomycin C was administered to 21 patients with metastatic transitional cell carcinoma of the urinary bladder. Of these, 19 patients were evaluable. Objective response occurred in four patients, or 21%. Hemopoietic depression was common and was dose related. Nephrotoxicity related to the drug was seen in one case. Mitomycin C does exhibit antitumor activity against transitional cell carcinoma in man.